Studies have demonstrated accelerated weight loss, a curb in appetite, improved control of eating, and many health benefits
Gastrointestinal (GI) side effects, such as nausea, diarrhea, and vomiting, are most commonly associated with this medication
MarburyTCFlintAJacobsenJBDerving KarsblJLasseterK
S.StoutD.et al (2006)
It sticks to FDA-approved medications only, which may limit flexibility during national shortages but helps avoid the safety and legal concerns associated with unregulated alternatives
Semaglutide (Ozempic, Wegovy, Rybelsus) Discontinuation : 161% increased risk Nausea : 246% increased risk Vomiting : 325% increased risk Diarrhea : 137% increased risk Tirzepatide (Mounjaro and Zepbound) Discontinuation : 130% increased risk Nausea : 261% increased risk Vomiting : 392% increased risk Diarrhea : 188% increased risk Cagrilintide/semaglutide (CargiSema) Discontinuation: 84% reduced risk Nausea: 721% increased risk Vomiting: 1724% increased risk Diarrhea: 560% increased risk Exenatide (Byetta and Bydureon) Discontinuation: 139% increased risk Nausea: 138% increased risk Vomiting: 182% increased risk Diarrhea: 103% increased risk The study comes just months after the U.S